Dynavax Technologies Corp
DVAX15.500USD
+0.010+0.06%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
1.82B시가총액
손실P/E TTM
자세한 내용은 Dynavax Technologies Corp 회사
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company developing and commercializing vaccines to help protect against infectious diseases. The Company has two commercial products: HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), and CpG 1018 adjuvant. The HEPLISAV-B vaccine is used for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose in-one-month adult hepatitis B vaccine. CpG 1018 adjuvant is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. The Company is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. Its pipeline programs include Shingles vaccine program (Z-1018) and Plague vaccine program. Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.
Dynavax Technologies Corp 정보
종목 코드 DVAX
회사 이름Dynavax Technologies Corp
상장일Feb 19, 2004
CEOSpencer (Ryan)
직원 수405
유형Ordinary Share
회계 연도 종료Feb 19
주소2100 Powell Street
도시EMERYVILLE
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호94608
전화15108485100
웹사이트https://www.dynavax.com/
종목 코드 DVAX
상장일Feb 19, 2004
CEOSpencer (Ryan)
Dynavax Technologies Corp의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Ryan Spencer
Mr. Ryan Spencer
Chief Executive Officer, Director
Chief Executive Officer, Director
396.09K
+118415.00%
Mr. David F. Novack
Mr. David F. Novack
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
109.97K
--
Dr. Robert (Rob) Janssen, M.D.
Dr. Robert (Rob) Janssen, M.D.
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
74.92K
--
Mr. John L. Slebir
Mr. John L. Slebir
Senior Vice President, General Counsel
Senior Vice President, General Counsel
63.47K
+32056.00%
Ms. Kelly MacDonald, CPA
Ms. Kelly MacDonald, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
56.49K
+30977.00%
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
29.86K
+5758.00%
Dr. Peter R. Paradiso, Ph.D.
Dr. Peter R. Paradiso, Ph.D.
Independent Director
Independent Director
24.83K
+5758.00%
Dr. Daniel L. (Dan) Kisner, M.D.
Dr. Daniel L. (Dan) Kisner, M.D.
Independent Director
Independent Director
23.33K
+5758.00%
Mr. Brent MacGregor
Mr. Brent MacGregor
Independent Director
Independent Director
21.83K
+5758.00%
Mr. Joseph Metzinger
Mr. Joseph Metzinger
Vice President, Chief Accounting Officer
Vice President, Chief Accounting Officer
7.13K
+7129.00%
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Ryan Spencer
Mr. Ryan Spencer
Chief Executive Officer, Director
Chief Executive Officer, Director
396.09K
+118415.00%
Mr. David F. Novack
Mr. David F. Novack
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
109.97K
--
Dr. Robert (Rob) Janssen, M.D.
Dr. Robert (Rob) Janssen, M.D.
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
74.92K
--
Mr. John L. Slebir
Mr. John L. Slebir
Senior Vice President, General Counsel
Senior Vice President, General Counsel
63.47K
+32056.00%
Ms. Kelly MacDonald, CPA
Ms. Kelly MacDonald, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
56.49K
+30977.00%
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
29.86K
+5758.00%
수익 분석
통화: USD마지막 업데이트: Tue, Jan 6
통화: USD마지막 업데이트: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
사업별USD
이름
수익
비율
HEPLISAV-B
89.95M
94.81%
Other revenue
4.92M
5.19%
지역별USD
이름
수익
비율
US
94.69M
99.81%
Non-US
183.00K
0.19%
사업별
지역별
사업별USD
이름
수익
비율
HEPLISAV-B
89.95M
94.81%
Other revenue
4.92M
5.19%
주식 보유 통계
마지막 업데이트: Sun, Nov 16
마지막 업데이트: Sun, Nov 16
주주
주주 유형
주주
주주
비율
Deep Track Capital LP
13.83%
BlackRock Institutional Trust Company, N.A.
12.93%
The Vanguard Group, Inc.
7.04%
State Street Investment Management (US)
5.53%
Millennium Management LLC
3.98%
기타
56.68%
주주
주주
비율
Deep Track Capital LP
13.83%
BlackRock Institutional Trust Company, N.A.
12.93%
The Vanguard Group, Inc.
7.04%
State Street Investment Management (US)
5.53%
Millennium Management LLC
3.98%
기타
56.68%
주주 유형
주주
비율
Hedge Fund
35.76%
Investment Advisor
35.71%
Investment Advisor/Hedge Fund
22.50%
Research Firm
6.27%
Pension Fund
1.19%
Individual Investor
0.84%
Bank and Trust
0.37%
Private Equity
0.04%
Sovereign Wealth Fund
0.03%
기관 주식 보유
마지막 업데이트: Mon, Dec 8
마지막 업데이트: Mon, Dec 8
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
546
115.83M
109.38%
+66.95K
2025Q3
565
115.78M
113.44%
+813.17K
2025Q2
563
116.95M
120.36%
-13.51M
2025Q1
558
131.20M
118.77%
-16.39M
2024Q4
550
133.28M
116.08%
-4.50M
2024Q3
545
132.56M
115.53%
-2.40M
2024Q2
531
134.71M
114.10%
-1.03M
2024Q1
527
135.87M
107.19%
-4.14M
2023Q4
514
128.04M
106.45%
-253.89K
2023Q3
500
128.23M
106.72%
-886.82K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Deep Track Capital LP
15.73M
13.83%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
14.70M
12.93%
-1.10M
-6.96%
Sep 30, 2025
The Vanguard Group, Inc.
8.08M
7.11%
-327.20K
-3.89%
Sep 30, 2025
State Street Investment Management (US)
6.29M
5.53%
-110.47K
-1.73%
Sep 30, 2025
Millennium Management LLC
4.53M
3.98%
+2.92M
+180.74%
Sep 30, 2025
Dimensional Fund Advisors, L.P.
3.57M
3.14%
-77.23K
-2.12%
Sep 30, 2025
Chicago Capital, LLC
4.31M
3.79%
-919.11K
-17.58%
Sep 30, 2025
Renaissance Technologies LLC
3.14M
2.76%
+252.02K
+8.73%
Sep 30, 2025
Two Sigma Investments, LP
3.01M
2.65%
-784.25K
-20.67%
Sep 30, 2025
Geode Capital Management, L.L.C.
2.53M
2.23%
-158.37K
-5.89%
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
Invesco Biotechnology & Genome ETF
2.91%
Virtus LifeSci Biotech Products ETF
1.58%
ETC 6 Meridian Small Cap Equity ETF
1.21%
Invesco S&P SmallCap Health Care ETF
0.62%
ETC 6 Meridian Low Beta Equity Strategy ETF
0.46%
Pacer US Small Cap Cash Cows Growth Leaders ETF
0.42%
State Street SPDR S&P Biotech ETF
0.41%
Themes US Small Cap Cash Flow Champions ETF
0.35%
Royce Quant Small-Cap Quality Value ETF
0.29%
Direxion Daily S&P Biotech Bull 3X Shares
0.25%
더 보기
Invesco Biotechnology & Genome ETF
비율2.91%
Virtus LifeSci Biotech Products ETF
비율1.58%
ETC 6 Meridian Small Cap Equity ETF
비율1.21%
Invesco S&P SmallCap Health Care ETF
비율0.62%
ETC 6 Meridian Low Beta Equity Strategy ETF
비율0.46%
Pacer US Small Cap Cash Cows Growth Leaders ETF
비율0.42%
State Street SPDR S&P Biotech ETF
비율0.41%
Themes US Small Cap Cash Flow Champions ETF
비율0.35%
Royce Quant Small-Cap Quality Value ETF
비율0.29%
Direxion Daily S&P Biotech Bull 3X Shares
비율0.25%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
